Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis
Article 2018 en
Authors
CK
Christoph Krisp
RP
Robert Parker
DP
Dana Pascovici
Abstract
1 min read
These results demonstrate the utility of proteomic phenotyping to identify both putative biomarkers of response to MEK inhibition and prognostication associated with metastatic melanoma.
Christoph Krisp, Robert Parker, Dana Pascovici, James S. Wilmott, John F. Thompson, Graham J. Mann, Richard A Scolyer, Nicholas K. Hayward, Mark P. Molloy
Jennifer A. Wargo, Rodabe N. Amaria, Merrick I. Ross, Robyn P.M. Saw, Jeffrey E. Gershenwald, Patrick Hwu, Sapna P. Patel, Isabella Claudia Glitza, Adi Diab, Richard Kefford, Richard A Scolyer, Helen Rizos, John F. Thompson, Kerwin F. Shannon, Andrew J. Spillane, Matteo S. Carlino, Alex Guminski, Lauren Simpson, Michael A. Davies, Georgina V. Long
Yi Lun Liu, Fritz Lai, James S. Wilmott, Xu Guang Yan, Xiao Ying Liu, Qi Luan, Su Guo, Chen Chen Jiang, Hsin‐Yi Tseng, Richard A Scolyer, Lei Jin, Xu Dong Zhang
James S. Wilmott, Lauren E. Haydu, Alexander M. Menzies, Trina Lum, Jessica Hyman, John F. Thompson, Peter Hersey, Richard Kefford, Richard A Scolyer, Georgina V. Long
Discussion(0)
No comments yet. Be the first to comment.